Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer ( TESS ): A study protocol of a prospective, open‐label, multicenter, single‐arm, phase 2 trial
Cancer Medicine · 2023
DOI: 10.1002/cam4.6034 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Cancer Medicine, 2023. Verfasst von Shuang Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Standard treatment of locally advanced rectal cancer (LARC) was neoadjuvant chemoradiotherapy (CRT), followed by total mesorectal excision (TME). Total neoadjuvant treatment (TNT), a new concept, attempts to deliver both systemic chemotherapy and neoadjuvant CRT prior to surgery. Patients treated with neoadjuvant chemotherapy were more likely to show higher tumor regression. The objective of this trial was to increase complete clinical rate (cCR) for LARC patients by optimizing tumor response, using TNT regimen as compared to conventional chemoradiotherapy. TESS, a prospective, open‐label, multicenter, single‐arm, phase 2 study, is underway.
Methods
Main inclusion criteria include cT3‐4aNany or cT1‐4aN+ rectal adenocarcinoma aged 18‐70y; Eastern Cooperative Oncology Group (ECOG) performance 0–1; location ≤5 cm from anal verge. Ninety‐eight patients will receive 2 cycles of neoadjuvant chemotherapy Capeox (capecitabine + oxaliplatin) before, during, and after radiotherapy 50Gy/25 fractions, before TME (or other treatment decisions, such as Watch and Wait strategy) and adjuvant chemotherapy capecitabine 2 cycles. Primary endpoint is the cCR rate. Secondary endpoints include ratio of sphincter preservation strategy; pathological complete response rate and tumor regression grade distribution; local recurrence or metastasis; disease‐free survival; locoregional recurrence‐free survival; acute toxicity; surgical complications; long‐term anal function; late toxicity; adverse effect, ECOG standard score, and quality of life. Adverse events are graded per Common Terminology Criteria for Adverse Events V5.0. Acute toxicity will be monitored during antitumor treatment, and late toxicity will be monitored for 3 years from the end of the first course of antitumor treatment.
Discussion
The TESS trial aims to explore a new TNT strategy, which is expected to increase the rate of cCR and sphincter preservation rate. This study will provide new options and evidence for a new sandwich TNT strategy in patients with distal LARC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
- Department of General Surgery, Shantou Central Hospital, Shantou, China.
- Department of Abdominal Surgery, Cancer Hospital of Shantou University Medical College, Shantou, China.
- Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
ORCID-Profile: Hui Chang, YuanHong Gao, WeiWei Xiao
Zitieren
APA
Liu, S., Wang, X., Zhuang, Y., Bai, S., Wu, X., Ye, Y., Luo, H., Yu, H., Wang, Q., Chang, H., Zeng, Z., Cai, P., Pan, Z., Gao, Y., Chen, G., & Xiao, W. (2023). Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer ( TESS ): A study protocol of a prospective, open‐label, multicenter, single‐arm, phase 2 trial. Cancer Medicine. https://doi.org/10.1002/cam4.6034
Vancouver
Liu S, Wang X, Zhuang Y, Bai S, Wu X, Ye Y, et al. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer ( TESS ): A study protocol of a prospective, open‐label, multicenter, single‐arm, phase 2 trial. Cancer Medicine. 2023. doi:10.1002/cam4.6034
BibTeX
@article{Liu2023,
author = {Liu, Shuang and Wang, XiaoZhong and Zhuang, YeZhong and Bai, ShouMin and Wu, XiaoJun and Ye, YiJing and Luo, HuiLong and Yu, HaiNa and Wang, QiaoXuan and Chang, Hui and Zeng, ZhiFan and Cai, PeiQiang and Pan, ZhiZhong and Gao, YuanHong and Chen, Gong and Xiao, WeiWei},
title = {Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer ( TESS ): A study protocol of a prospective, open‐label, multicenter, single‐arm, phase 2 trial},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6034}
}
EUVIMED